Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy targeting the CD-19 B-cell receptor has emerged as an efficacious and life-extending treatment modality with high response rates and durable remissions in patients with relapsed and refractory non-Hodgkin lymphoma (NHL) [1], follicular lymphoma [2], and B-cell acute lymphoblastic leukemia (B-ALL) [3]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.